Page values for "WSI23-88-Case-8"
From MGH Learn Pathology
Contents
[hide]"_pageData" values
_creationDate | May 23, 2023 |
_modificationDate | December 9, 2024 |
_creator | Kx601 |
_fullText | {{ServiceRequestCase |requisition=Current Concepts in Head and Neck and Endocrine Pathology |subject=MGH |intent=order |occurrenceDateTime=2023/06/09 05:00 |basedOn=WSI23-88 |priority=routine |code=study |orderDetail=case |authoredOn=May 23, 2023 05:15:30 PM |requester=Kx601 |locationCode=learn |seq ... |
_numRevisions | 2 |
_isRedirect | No |
"_fileData" values
"ServiceRequest" values
identifier | WSI23-88-Case-8 |
basedOn | WSI23-88 |
requisition | Current Concepts in Head and Neck and Endocrine Pathology |
intent | order |
category | null |
priority | routine |
code | study |
orderDetail | case |
subject | MGH |
occurrenceDateTime | June 9, 2023 5:00:00 AM |
authoredOn | May 23, 2023 5:15:30 PM |
requester | Kx601 |
performer | pms36 |
locationCode | learn |
reasonCode | 33 year old diagnosed with papillary thyroid carcinoma in 2012. Lesion was a 2.0 cm in the right lobe with minimal extrathyroidal extension and two negative lymph nodes (currently would have been classified as pT1b N0a -- then pT3 N0). All was fine until July 2020 noted to have LUL lung lesion excised and RUL lung lesion excised Aug 2020. Jan 2021 • noted to have two brain lesions (L frontoparietal and R occipital). Tumor noted to have CCDC149-ALK fusion. Subsequently treated with SAS (stereotactic ablative surgery -- gamma knife). Now alectinib. |
supportingInfo | Kinase fusion-related thyroid carcinoma (for now • associated with classical papillary thyroid carcinoma). Alectinib targets ALK (anaplastic lymphoma kinase) |
specimen | null |
bodySite | Thyroid |
sequence | 8 |
access | private |
"Media" values
identifier | WSI22-66-Case-1_1 |
basedOn | WSI23-88-Case-8 |
partOf | WSI23-88 |
status | completed |
type | image |
modality | mrxs |
view | show |
createdDateTime | May 23, 2023 5:15:30 PM |
operator | Kx601 |
reasonCode | H&E |
bodySite | null |
frames | 1 |
content | WSI22-66-Case-1_1.mrxs |
note | null |
subject | Z0FBQUFBQmtiUFRzczUxbWtKM1o1cEozRFZHMjNHdzBzY1RuUmZ1VGpOZWFTaHhwdlkwTmk3TEZIRU4xajd0d241VlFKRWtSaV9ua2RkbVdILWRoRmJFQW1oU2ExT0dmSkE9PQ |
identifier | WSI22-66-Case-1_2 |
basedOn | WSI23-88-Case-8 |
partOf | WSI23-88 |
status | completed |
type | image |
modality | mrxs |
view | show |
createdDateTime | May 23, 2023 5:15:30 PM |
operator | Kx601 |
reasonCode | H&E |
bodySite | null |
frames | 2 |
content | WSI22-66-Case-1_2.mrxs |
note | null |
subject | Z0FBQUFBQmtiUFVkUWRJZS1iVHFGbmdic3BWcVlZNkh4cVpncGtDSkh4amt4SmNsVWdqQlVmSXNDWTRLd1V1VzhKb214endHSDNqQU16UWh3UHFBTXI1TzhBTGJJREp5b1NJNTBmMVgwRVFSMlpWMlAtZnBzMms9 |
identifier | WSI22-66-Case-1_3 |
basedOn | WSI23-88-Case-8 |
partOf | WSI23-88 |
status | completed |
type | image |
modality | mrxs |
view | show |
createdDateTime | May 23, 2023 5:15:30 PM |
operator | Kx601 |
reasonCode | H&E |
bodySite | null |
frames | 3 |
content | WSI22-66-Case-1_3.mrxs |
note | null |
subject | Z0FBQUFBQmtiUFVsdGJZQ0JfQWFvVWNpajZsQWczYVJnVHBOYkxvZ2xYb3o1MlRRbFg1SWp2RFN4dzRVTlVwdktlOEdGaTJmWks0aWl3NTI5TjNmNURYdE4tZWR1ZDRHOXdTXzQ5bTdZeDNtSmpmY1JmVGRXSm89 |
identifier | WSI22-66-Case-1_4 |
basedOn | WSI23-88-Case-8 |
partOf | WSI23-88 |
status | completed |
type | image |
modality | mrxs |
view | show |
createdDateTime | May 23, 2023 5:15:30 PM |
operator | Kx601 |
reasonCode | H&E |
bodySite | null |
frames | 4 |
content | WSI22-66-Case-1_4.mrxs |
note | null |
subject | Z0FBQUFBQmtiUFVtQ0M3U1BuazJFQURDTVNFQ1lpOWk3TUNtM0E3TUtkcXlsZ0ZZdF9pUkRzaVJ3Tlg0RDNGekgwUjJHMVZxcHhTcXVpUEZBZTZhYWhwMUV0dVltT21PNEE9PQ |
"status" values
status | active |
identifier | WSI23-88-Case-8 |
requester | Kx601 |
authoredOn | May 23, 2023 5:15:30 PM |